The more advanced precursor condition, smoldering multiple myeloma (SMM), represents an intermediary disease state between MGUS and MM, and is defined by monoclonal bone marrow plasma cells (BMPC) > 10% and/or an M-protein level ≥30 g/L, without evidence of end-organ damage i.e., CRAB criteria or other myeloma defining events [2]. Here, MYOM2 is linked to plasma cell myeloma.